By any standard, the pharmaceutical industry's history has been a
successful one. In addition to its profits and shareholder
dividends, it has been seen by investors as relatively low risk
and, largely, counter-cyclical to stock market trends. However,
that important contribution appears to be petering out, with
significant global implications for employees, shareholders,
governments and patients. This is not just caused by the economic
crisis. Long... more...